NASH

Metabolic Diseases
4
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Madrigal Pharmaceuticals
REZDIFFRAApproved
resmetirom
Madrigal Pharmaceuticals
Thyroid Hormone Receptor beta Agonist [EPC]oral2024

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Madrigal Pharmaceuticals
Madrigal PharmaceuticalsWEST CONSHOHOCKEN, PA
1 program
1
1
ResmetiromPhase 31 trial
Active Trials
NCT05500222Active Not Recruiting700Est. Jan 2027
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
chiglitazar sodium tabletsPhase 21 trial
Active Trials
NCT05193916CompletedEst. Jan 2024
89bio
89bioCA - San Francisco
1 program
1
PegozaferminPhase 1/21 trial
Active Trials
NCT04048135Completed101Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Madrigal PharmaceuticalsResmetirom
Chipscreen Bioscienceschiglitazar sodium tablets
89bioPegozafermin

Clinical Trials (3)

Total enrollment: 801 patients across 3 trials

NCT05500222Madrigal PharmaceuticalsResmetirom

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Start: Aug 2022Est. completion: Jan 2027700 patients
Phase 3Active Not Recruiting
NCT05193916Chipscreen Bioscienceschiglitazar sodium tablets

A Phase II Clinical Trial of Chiglitazar for NASH

Start: Mar 2022Est. completion: Jan 2024
Phase 2Completed
NCT0404813589bioPegozafermin

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Start: Jul 2019Est. completion: Jan 2022101 patients
Phase 1/2Completed

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
5h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
23h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Diagnostics Value Consultant(Product Marketing) - Diabetes Care Portfolio

Roche
Taipei
4d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)